Intra-Articular, Single-shot Injection of Hyaluronic Acid and Corticosteroids in Knee Osteoarthritis
Launched by ZHONGDA HOSPITAL · Feb 7, 2017
Trial Information
Current as of June 18, 2025
Unknown status
Keywords
ClinConnect Summary
Intra-articular injection of hyaluronic acid (HA) or corticosteroids (CS) has been widely used with debate on its efficacy in osteoarthritis (OA). The aim of present study is to to investigate whether the combined injection of HA and CS is superior than HA alone in the treatment of knee OA.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • According to radiographic findings, patients who are suffering from knee OA for over 3 months have to be stage II-IV according to the Kellgren-Lawrence (KL) grade by a senior radiologist. The diagnosis of symptomatic knee OA is based on American Rheumatism Association classification criteria for knee osteoarthritis.
- Exclusion Criteria:
- • Exclusion criteria are the diagnosis of rheumatoid arthritis or other inflammatory OA, presence of trauma or pain-causing diseases, treatment with oral medications in recent 3 days, physiotherapy and intra-articular injection of HA or CS in the past 6 months. Participants who are allergic to any of the medications used in this study or diagnosed with current systemic infection are also excluded.
About Zhongda Hospital
Zhongda Hospital, a leading medical institution affiliated with Southeast University in Nanjing, China, is dedicated to advancing healthcare through innovative research and clinical trials. With a robust focus on patient-centered care, the hospital combines cutting-edge facilities with a multidisciplinary team of experts to conduct a wide range of clinical studies. Zhongda Hospital is committed to enhancing medical knowledge and improving treatment outcomes across various specialties, fostering collaboration between researchers and healthcare professionals to ensure the highest standards of scientific rigor and ethical practice in all its clinical endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nanjing, Jiangsu, China
Patients applied
Trial Officials
Shan-zheng Wang, MD
Principal Investigator
Zhongda Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials